Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.

MLA

ahn, Jae-Sook, et al. “Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.” Acta Haematologica, vol. 134, no. 1, June 2015, pp. 40–48. EBSCOhost, https://doi.org/10.1159/000368711.

APA

ahn, J.-S., Kim, Y.-K., Min, Y. H., Cheong, J.-W., Jang, J. H., Jung, C. W., Kim, I. H., Yoon, H.-J., Lee, H. G., Sohn, S. K., Moon, J. H., Kim, H., Kim, Y.-J., Won, J.-H., Chung, J.-S., Mun, Y. C., Lee, J.-H., & Kim, H.-J. (2015). Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. Acta Haematologica, 134(1), 40–48. https://doi.org/10.1159/000368711

Chicago

ahn, Jae-Sook, Yeo-Kyeoung Kim, Yoo Hong Min, June-Won Cheong, Jun Ho Jang, Chul Won Jung, In Ho Kim, et al. 2015. “Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome.” Acta Haematologica 134 (1): 40–48. doi:10.1159/000368711.